[go: up one dir, main page]

PL2158315T3 - Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych - Google Patents

Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych

Info

Publication number
PL2158315T3
PL2158315T3 PL08757278.0T PL08757278T PL2158315T3 PL 2158315 T3 PL2158315 T3 PL 2158315T3 PL 08757278 T PL08757278 T PL 08757278T PL 2158315 T3 PL2158315 T3 PL 2158315T3
Authority
PL
Poland
Prior art keywords
antibodies
methods
functional properties
improved functional
modifying
Prior art date
Application number
PL08757278.0T
Other languages
English (en)
Inventor
David Urech
Leonardo Borras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39820887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2158315(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2158315T3 publication Critical patent/PL2158315T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08757278.0T 2007-06-25 2008-06-25 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych PL2158315T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93711207P 2007-06-25 2007-06-25
US6905608P 2008-03-12 2008-03-12

Publications (1)

Publication Number Publication Date
PL2158315T3 true PL2158315T3 (pl) 2016-10-31

Family

ID=39820887

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08757278.0T PL2158315T3 (pl) 2007-06-25 2008-06-25 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych

Country Status (20)

Country Link
US (2) US20090074780A1 (pl)
EP (1) EP2158315B1 (pl)
JP (5) JP5611820B2 (pl)
KR (1) KR101573086B1 (pl)
CN (6) CN106366192B (pl)
AU (1) AU2008267734B9 (pl)
BR (1) BRPI0813645A2 (pl)
CA (1) CA2689941C (pl)
DK (1) DK2158315T3 (pl)
ES (1) ES2566737T3 (pl)
HR (1) HRP20160730T1 (pl)
HU (1) HUE027507T2 (pl)
IL (1) IL202360A (pl)
MX (1) MX2009013328A (pl)
NZ (2) NZ601946A (pl)
PL (1) PL2158315T3 (pl)
RU (3) RU2540150C2 (pl)
SI (1) SI2158315T1 (pl)
WO (1) WO2009000099A2 (pl)
ZA (1) ZA200908384B (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101222758B (zh) 2007-01-08 2011-10-26 中兴通讯股份有限公司 一种在高速分组数据网传递1x寻呼被拒绝的方法
EP3202786A3 (en) * 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
JP5611820B2 (ja) * 2007-06-25 2014-10-22 エスバテック − ア ノバルティスカンパニー エルエルシー 抗体の修飾方法並びに改善された機能特性を有する修飾された抗体
CA2689064C (en) 2007-06-25 2018-04-24 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
NZ623716A (en) 2008-04-11 2016-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2727839C (en) 2008-06-25 2018-11-20 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
DK3241843T3 (da) 2008-06-25 2021-09-06 Novartis Ag Opløselighedsoptimering af immunbindere
EP3858854A1 (en) 2008-06-25 2021-08-04 Novartis AG Stable and soluble antibodies inhibiting tnf
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
RU2016108598A (ru) * 2008-06-30 2018-11-23 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
AR079114A1 (es) 2009-11-20 2011-12-28 Amgen Inc Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
KR102344129B1 (ko) 2010-10-08 2021-12-30 시티 오브 호프 메디토프를 위한 단일클론 항체 프레임워크 결합 계면, 메디토프 전달 시스템 및 이의 사용 방법
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AU2013203189B2 (en) * 2010-10-22 2014-12-11 Novartis Ag Stable and soluble antibodies
AU2016277637B2 (en) * 2010-10-22 2018-11-08 Novartis Ag Stable and soluble antibodies
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
JP6076357B2 (ja) * 2011-10-10 2017-02-08 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ メディトープおよびメディトープ結合性抗体ならびにそれらの使用
RU2652886C2 (ru) * 2011-10-20 2018-05-03 ИЭсБиЭйТЕК-Э НОВАРТИС КОМПАНИ ЭлЭлСи Стабильные антитела, связывающиеся с несколькими антигенами
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA3202536A1 (en) 2012-05-10 2013-11-14 Bioatla, Llc Multi-specific monoclonal antibodies
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
CN105579472B (zh) 2013-06-26 2021-10-22 努玛医疗技术有限公司 新型抗体框架
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
BR112016026773A2 (pt) 2014-05-16 2017-12-12 Ablynx Nv domínios variáveis de imunoglobulina aperfeiçoados
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3350216A1 (en) 2015-09-15 2018-07-25 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
BR112018067696A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag membros de ligação à pd-l1
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
WO2018175310A1 (en) * 2017-03-20 2018-09-27 Cancer Therapeutics Laboratories, Inc. Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
MX2021007997A (es) * 2019-01-03 2021-08-16 Amgen Inc Ingenieria de anticuerpos monoclonales para mejorar la estabilidad y titulo de produccion.
JP7500619B2 (ja) 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
EP3767628B1 (de) * 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Selektion von antikörpern / antikörperfragmenten
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
MX2022005965A (es) 2019-11-19 2022-08-08 Amgen Inc Formato de anticuerpos multiespecíficos novedosos.
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
US20230322955A1 (en) 2020-08-20 2023-10-12 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
AU2021379598A1 (en) 2020-11-10 2023-06-08 Amgen Inc. Novel linkers of multispecific antigen binding domains
US20220259296A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
WO2022190009A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
EP4326761A1 (en) 2021-04-20 2024-02-28 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
MX2024007473A (es) 2021-12-14 2024-09-10 Cdr Life Ag Activador del linfocito t dirigido al mhc doble.
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024251780A1 (en) * 2023-06-05 2024-12-12 Sanofi Predicting properties of single variable domains using machine-learning models

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197800A (en) * 1983-05-02 1985-12-10 William O. Weigle Immune modulator peptides
EP1362868A3 (en) 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
EP0519596B1 (en) * 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
DE69427974T2 (de) * 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6673901B2 (en) * 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP2990054A1 (en) 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
EP1242457B1 (en) * 1999-12-28 2004-08-11 Esbatech AG Intrabodies with defined framework that is stable in a reducing environment and applications thereof
IL152738A0 (en) * 2000-05-10 2003-06-24 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
KR20030041164A (ko) 2000-10-13 2003-05-23 바이오겐, 인코포레이티드 인간화된 항-ＬＴ-β-Ｒ 항체
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
EP1401470A4 (en) * 2001-06-04 2005-05-25 Curagen Corp NEW ANTIBODIES BINDING TO ANTIGENIC POLYPEPTIDES, THE ANTIGENE ENCODING NUCLEIC ACIDS AND METHOD FOR THEIR USE
US20060127893A1 (en) * 2001-07-19 2006-06-15 Stefan Ewert Modification of human variable domains
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
DE60232101D1 (pl) 2001-12-28 2009-06-04 Kyowa Hakko Kogyo Kk
US6905608B2 (en) 2002-01-22 2005-06-14 Exergy Technologies Corporation Advanced electrodeionization for fluid recycling
CA2483285C (en) 2002-05-22 2015-01-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2005532051A (ja) 2002-07-01 2005-10-27 バイオジェン， インコーポレイテッド ヒト化抗リンホトキシンβレセプター抗体
US7300655B2 (en) 2002-08-01 2007-11-27 Immunomedics, Inc. Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
RS51318B (sr) * 2002-12-16 2010-12-31 Genentech Inc. Varijante imunoglobulina i njihova upotreba
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
AU2004255553B2 (en) 2003-06-19 2009-08-20 Genentech, Inc. Compositions and methods for treating coagulation related disorders
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
MX337587B (es) 2003-11-05 2016-03-11 Glycart Biotechnology Ag Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas.
JP4869074B2 (ja) * 2003-11-28 2012-02-01 アストラゼネカ アーベー 抗体
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
CA2564251C (en) 2004-05-21 2018-04-10 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
KR101228157B1 (ko) 2004-05-27 2013-01-31 크루셀 홀란드 비.브이. 광견병 바이러스를 중화시킬 수 있는 결합 분자 및 그 용도
GB0416651D0 (en) * 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CA2599734C (en) 2005-03-03 2014-01-28 Immunomedics, Inc. Humanized l243 antibodies
CA2868865A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method of isolation of soluble polypeptides
EP1889908A4 (en) 2005-06-03 2012-04-25 Mochida Pharm Co Ltd PROTEIN FUSED WITH ANTI-CD14 ANTIBODY
US8067547B2 (en) * 2005-06-07 2011-11-29 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting TNFα
KR20080030960A (ko) 2005-07-05 2008-04-07 글락소 그룹 리미티드 Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
KR101460932B1 (ko) 2005-08-26 2014-11-12 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
CA2627446A1 (en) * 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
EP2481753B1 (en) * 2005-12-13 2018-04-18 Eli Lilly and Company Anti-IL-17 Antibodies
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
US8936785B2 (en) * 2006-07-10 2015-01-20 ESBATech, an Alcon Biomedical Research Unit, LLC scFv antibodies which pass epithelial and/or endothelial layers
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101210241A (zh) * 2006-12-27 2008-07-02 陕西超英生物科技有限公司 一种噬菌体基因工程抗体库基因组装的方法
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CA2689064C (en) 2007-06-25 2018-04-24 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
JP5611820B2 (ja) 2007-06-25 2014-10-22 エスバテック − ア ノバルティスカンパニー エルエルシー 抗体の修飾方法並びに改善された機能特性を有する修飾された抗体
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法

Also Published As

Publication number Publication date
NZ581468A (en) 2012-09-28
DK2158315T3 (en) 2016-06-06
EP2158315A2 (en) 2010-03-03
WO2009000099A3 (en) 2009-04-09
JP2019141091A (ja) 2019-08-29
NZ601946A (en) 2013-12-20
JP6129797B2 (ja) 2017-05-17
WO2009000099A2 (en) 2008-12-31
JP2021119782A (ja) 2021-08-19
CN101849001B (zh) 2014-07-16
KR101573086B1 (ko) 2015-11-30
EP2158315B1 (en) 2016-03-23
US20190002551A1 (en) 2019-01-03
US20090074780A1 (en) 2009-03-19
CA2689941A1 (en) 2008-12-31
HRP20160730T1 (hr) 2016-07-15
RU2014142680A (ru) 2016-05-20
CN106366192B (zh) 2020-03-27
RU2019118109A (ru) 2020-12-11
AU2008267734B2 (en) 2014-07-24
AU2008267734B9 (en) 2014-09-11
JP2010531145A (ja) 2010-09-24
CN111253484A (zh) 2020-06-09
ZA200908384B (en) 2011-02-23
CN103435696B (zh) 2016-10-12
CN102838673A (zh) 2012-12-26
KR20100028575A (ko) 2010-03-12
RU2010102065A (ru) 2011-07-27
CN103435696A (zh) 2013-12-11
JP5611820B2 (ja) 2014-10-22
RU2540150C2 (ru) 2015-02-10
BRPI0813645A2 (pt) 2014-12-30
CN102838673B (zh) 2016-05-11
HK1137483A1 (zh) 2010-07-30
JP2015007104A (ja) 2015-01-15
ES2566737T3 (es) 2016-04-15
IL202360A (en) 2015-07-30
HUE027507T2 (en) 2016-10-28
IL202360A0 (en) 2011-08-01
JP2017186338A (ja) 2017-10-12
SI2158315T1 (sl) 2016-05-31
RU2014142680A3 (pl) 2018-05-28
AU2008267734A1 (en) 2008-12-31
CN105017427A (zh) 2015-11-04
CA2689941C (en) 2019-10-29
CN106366192A (zh) 2017-02-01
MX2009013328A (es) 2010-06-02
CN101849001A (zh) 2010-09-29

Similar Documents

Publication Publication Date Title
ZA200908384B (en) Methods of modifying antibodies, and modified antibodies with improved functional properties
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
EP2347038A4 (en) METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL241091A0 (en) Antibodies to fcrn and their use
IL216731A (en) And antibodies against p95 – her2 and their uses
PT2373691T (pt) Anticorpos anti-fxi e métodos de utilização
EP2334330A4 (en) ANTI-CD147 ANTIBODIES, METHODS, AND USES
EP2247305A4 (en) STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF
AP2929A (en) Anti-TRKA antibodies and derivatives thereof
IL210643A0 (en) Anti-hepcidin-25 selective antibodies and uses thereof
IL211623A0 (en) Anti-notch2 antibodies and methods of use
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
IL205355A0 (en) Anti- hepcidin antibodies and uses thereof
IL196960A0 (en) Anti-c5ar antibodies with improved properties
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL212040A0 (en) Hepatitis c antibodies and uses thereof
IL236237A (en) Tmem154 antibodies and their segments and uses
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2074258A4 (en) FIBER PLATES, THEIR MANUFACTURE AND USE